

Reference: FOI.ICB-2324/359

Subject: Primary Care Rebate Schemes

I can confirm that the ICB does hold the information requested; please see responses below:

QUESTION	RESPONSE				
<p>I would be grateful if you could confirm what primary care rebate schemes your ICB/ Board currently hold (brand & generic name and company if possible)?</p> <p>What are the start and end dates of the schemes? Or is it an ongoing scheme?</p>	Rebate Product	Generic name/ product	Company	Start date	End date
	Adcal D3	<i>colecalciferol</i>	Kyowa Kirin	01/04/2018	Until termination
	BD Viva	<i>Pre-filled insulin Pen needles</i>	Becton Dickinson UK Limited	Dates deemed commercially sensitive.	
	Butec	<i>buprenorphine patches</i>	QDEM	01/04/2021	30/04/2024
	Buvidal	<i>buprenorphine P/R solution for injection</i>	Camurus	01/07/2021	31/12/2023
	Clenil	<i>CFC-free beclometasone</i>	Chiesi	01/07/2022	30/06/2024
	Espranor	<i>buprenorphine oral lyophilisate</i>	Ethypharm	28/11/2023	31/12/2025
	Fostair NEXThaler	<i>beclometasone dipropionate/for moterol fumarate dihydrate pressurised metered dose</i>	Chiesi	01/10/2023	30/09/2025

	Fostair pMDI	<i>beclometasone dipropionate/for moterol fumarate dihydrate dry powder inhaler</i>	Chiesi	01/10/2023	30/09/2025
	FreeStyle Libre	<i>FreeStyle Libre sensor, FreeStyle Libre2 sensor</i>	Abbott Laboratories Limited	01/09/2022	31/08/2024
	Gatalin XL	<i>galantamine</i>	Aspire Pharma	01/12/2023	30/11/2024
	Glucophage	<i>metformin</i>	Merck Serono (Brand Life Pharma)	01/07/2022	30/06/2024
	Onglyza	<i>saxagliptin</i>	AstraZeneca	Roll on of previous agreement	Until termination
	Pipexus	<i>pramipexole PR tablets</i>	Ethypharm	01/11/2019	Until terminated
	Prostap	<i>Leuprorelin DCS (& DCS SR)</i>	Takeda	Dates deemed commercially sensitive.	
	Ranexa	<i>ranolazine</i>	A. Menarini Farmaceutica Internazionale SRL	01/10/2022	30/09/2024
	Stexerol	<i>colecalfiferol</i>	Kyowa Kirin	01/10/2018	Until terminated
	Strivit	<i>Colecalciferol</i>	Strides Pharma	01/04/2021	31/03/2024
	Vizidor & Vizidor Duo	<i>Dorzolamide hydrochloride/dorzolamide hydrochloride timolol maleate</i>	Bausch & Lomb U.K. Limited	01/09/2023	31/08/2025

	Xaggitin	<i>methylphenidate</i>	Ethypharm	01/04/2018	Until terminated
	National procurement for direct acting oral anticoagulants (DOACs)			01/01/2022	31/03/2024
<p>The ICB has applied Section 43(2) (Information prejudice to commercial interests) to the response. The public interest arguments in favour of disclosing the information include the ICB's responsibility to be transparent and accountable in its decision making. The ICB policy for Sponsorship of Activities by and Joint Working with the Pharmaceutical Industry outlines the values the ICB adheres to when working with the pharmaceutical industry and this includes the principle for the ICB to promote confidence between staff, patients and the public through transparency of NHS activities. The policy also outlines that information relating to rebate schemes is disclosable under the FOI Act and only information considered commercially sensitive should be redacted.</p> <p>The public interest arguments in favour of maintaining the exemption includes the agreement signed by the ICB which confirms the information as commercially sensitive and the subsequent confirmation of this from the contract holder as well as their reasoning for why they consider the information commercially sensitive. Rebate schemes allow organisations to offer a financial rebate to the ICB and these schemes are considered on clinical, financial and contractual grounds and will only be considered if the</p>					

	<p>medicines are appropriate and of value to the ICB population. The ICB has considered that disclosure of the information may lead to the contract holder not offering this type of scheme again which may result in the ICB having to spend more public funds on prescribing. The ICB has a responsibility to secure the best use of public resources and provide value for money.</p> <p>The ICB has considered the balance of both disclosing the information and maintaining the exemption and believes that it is in the public's best interest to apply the exemption. The ability for organisations to offer rebate schemes to the ICB reduces the amount of public funding used for prescribing and allows for the more effective use of resources to ensure that the ICB achieves value for money.</p>
--	--

The information provided in this response is accurate as of 2 January 2024 and has been approved for release by Dr Geeta Iyer, Deputy Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.